|Sachdev D, Chirgwin JM. Solubility of proteins isolated from inclusion bodies is enhanced by fusion to maltose-binding protein or thioredoxin. Protein Exp Purif. 12:122-132, 1998. |
Sachdev D, Chirgwin JM. Order of fusions between mammalian and bacterial proteins can determine solubility in Escherichia coli. Biochem Biophys Res Commun. 244:933-937, 1998.
Sachdev D, Chirgwin JM. Epitope mapping of recombinant human procathepsin D. Advan Experimental Med and Biol. 436:185-189, 1998.
Chirgwin JM, Schultz S, Sachdev D. Expression of chimeric human aspartic proteinases. Advan Experimental Med and Biol. 436:139-146, 1998.
Sachdev D, Chirgwin JM. Properties of soluble fusions between mammalian aspartic proteinases and bacterial maltose-binding protein. J Protein Chem. 18:127-136, 1999.
Sachdev D, Chirgwin JM. Fusions to maltose-binding protein to control folding and solubility. Methods Enzymol. 326:312-21, 2000.
Sachdev D, Yee D. The IGF system and breast cancer. Endocr Relat Cancer. 8:197-209, 2001.
Lee AV, Schiff R, Cui X, Sachdev D, Yee D, Gilmore AP, Streuli CH, Oesterreich S, Hadsell DL. New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation. Clin Cancer Res. 9:516S-23S, 2003.
Sachdev D, Li S, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res. 63:627-35, 2003.
Ye J, Liang S, Guo N, Li S, Wu AM, Giannini S, Sachdev D, Yee D, Brunner N, Ikle D, Fujita-Yamaguchi, Y. Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo. Horm Metab Res. 35:836-842, 2003.
Sachdev D, Hartell JS, Lee AV, Zhang X, Yee D. A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem. 279(6):5017-24, 2004.
Zhang X, Kamaraju S, Hakuno F, Kabuta T, Takahashi S, Sachdev D, Yee D. Motility response to insulin-like growth factor-I (IGF-I) in MCF-7 cells is associated with IRS-2 activation and integrin expression. Breast Cancer Res Treat. 83:161-170, 2004.
Sachdev D, Singh R, Fujita-Yamaguchi Y, Yee D. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: Implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res. 66:2391-402, 2006.
Sachdev D, Yee D. Inhibitors of insulin-like growth factor signaling: A therapeutic approach for breast cancer. J Mammary Gland Biol and Neoplasia. 11:27-39, 2006.
Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther. 6:1-12, 2007.
Sachdev D. Drug evaluation: CP-751871, a human antibody against type I insulin-like growth factor receptor for the potential treatment of cancer. Curr Opin Mol Ther. 9(3):299-304, 2007.
Sachdev D. Regulation of breast cancer metastasis by IGF signaling. J Mammary Gland Biol Neoplasia. 2008; 13: 431-41.
Zeng X, Sachdev D, Zhang H, Gaillard-Kelly M, Yee D. Sequencing of Type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo. Clin Cancer Res. 2009 Apr 15;15(8):2840-9.
Oh S, Stish BJ, Sachdev D, Chen H, Dudek AZ, Vallera DA. A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma. Clin Cancer Res. 2009 Oct 1;15(19):6137-47.
Sachdev D, Zhang X, Matise I, Gaillard-Kelly M, Yee D. The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene. 2010 Jan 14;29(2):251-62.
Zhang H, Fagan DH, Zeng X, Freeman KT, Sachdev D, Yee D. Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene. 2010 Apr 29;29(17):2517-27.
Sachdev D. Targeting the type I insulin-like growth factor system for breast cancer therapy. Curr Drug Targets. 2010 Sep;11(9):1121-32. Review.